Pacer Advisors
XLRN

Pacer Advisors’s Acceleron Pharma XLRN Stock Holding History

Pacer Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-568
Closed -$77K – 1605
2021
Q1 		$77K Sell
568
-492
-46% -$63.6K ﹤0.01% 1336
2020
Q4 		$136K Sell
1,060
-44
-4% -$5.16K ﹤0.01% 1307
2020
Q3 		$124K Buy
+1,104
New +$110K ﹤0.01% 1231
2018
Q4 		– Sell
-2,960
Closed -$169K – 1128
2018
Q3 		$169K Buy
+2,960
New +$145K 0.01% 1046
2018
Q1 		– Sell
-725
Closed -$31K – 1155
2017
Q4 		$31K Buy
+725
New +$27.2K ﹤0.01% 1064

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Pacer Advisors's XLRN Position: Q2 2021 in Review

Pacer Advisors sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 568 shares — an estimated $77K sold.

Pacer Advisors first reported a position in XLRN in Q4 2017 and held it in 5 quarters. The position peaked at $169K in Q3 2018. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Pacer Advisors reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 568 Acceleron Pharma shares in Q2 2021, an estimated $77K.
  • Pacer Advisors first reported a position in Acceleron Pharma in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's Acceleron Pharma position peaked at $169K in Q3 2018.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.